Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.

An approach to stimulating an immune response against tumors is to transduce tumor cells with bacterial genes, which represent a "danger signal" and can induce a wide immune response. Mycobacterium tuberculosis genes and their encoded proteins play a pivotal role in linking innate and cell-mediated adaptive immunity and represent ideal candidates as immune adjuvants for tumor vaccines. The efficacy of a cancer vaccine, obtained by transduction of a mammary tumor cell line with the M. tuberculosis Ag38 gene, was investigated in female mice transgenically expressing the rat HER-2/neu proto-oncogene. These mice spontaneously develop stochastic mammary tumors after a long latency period. The onset of spontaneous mammary tumors was significantly delayed in mice vaccinated with Ag38-transduced cells but not in mice vaccinated with nontransduced cells as compared with untreated mice. Protection from spontaneous tumor development was increased when mice were vaccinated with the mycobacterium gene-transduced vaccine plus a systemic administration of interleukin 12 (IL-12) at a low dose. Mice vaccinated with nontransduced cells plus IL-12 developed tumors, with only a slight delay in tumor appearance as compared with the control group. Lymphocytes obtained from lymph nodes of mice vaccinated with transduced cells secreted high levels of IFN-gamma. CD3+CD8+ spleen cells derived from these mice responded to the tumor with IFN-gamma production. These data indicate the efficacy of a short-term protocol of vaccinations exploiting the adjuvant potency of a M. tuberculosis gene and low doses of IL-12 in a model of stochastic development of mammary tumors. This adjuvant approach may represent a promising immunotherapeutic strategy for cancer immunization.

[1]  S. Ménard,et al.  High level antibody response to retrovirus‐associated but not to melanocyte lineage‐specific antigens in mice protected against B16 melanoma , 1999, International journal of cancer.

[2]  J. Neefjes,et al.  Recycling MHC class I molecules and endosomal peptide loading. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Heath,et al.  Cytotoxic T lymphocyte activation by cross-priming. , 1999, Current opinion in immunology.

[4]  H. Fujiwara,et al.  Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine , 1998, Gene Therapy.

[5]  J. Harty,et al.  CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. , 1998, Journal of immunology.

[6]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[7]  S. Ménard,et al.  Anti-tumor immunity induced by murine melanoma cells transduced with the Mycobacterium tuberculosis gene encoding the 38-kDa antigen , 1998, Gene Therapy.

[8]  G. Trinchieri,et al.  Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. , 1998, Cancer research.

[9]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[10]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[11]  H. Vordermeier,et al.  Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. , 1997, Journal of immunology.

[12]  M. Colombo,et al.  Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. , 1996, Journal of immunology.

[13]  A. Sher,et al.  IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. , 1996, Journal of immunology.

[14]  A. Krieg.  An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. , 1996, The Journal of laboratory and clinical medicine.

[15]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[16]  L. Zitvogel,et al.  Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors , 1996, European journal of immunology.

[17]  Albert R. Jonsen,et al.  The advent of the ‘unpatients’ , 1996, Nature Medicine.

[18]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Lehmann,et al.  Induction of TH1 and TH2 Immunity in Neonatal Mice , 1996, Science.

[20]  M. Colombo,et al.  Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. , 1996, Cancer research.

[21]  A. Porgador,et al.  Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. , 1995, Cancer research.

[22]  G. Trinchieri,et al.  B7-1 and interleukin 12 synergistically induce effective antitumor immunity. , 1995, Cancer research.

[23]  G. Rook,et al.  Tuberculosis and cancer: parallels in host responses and therapeutic approaches? , 1995, The Lancet.

[24]  G. Trinchieri,et al.  Interleukin‐12 is required for interferon‐γ production and lethality in lipopolysaccharide‐induced shock in mice , 1995, European journal of immunology.

[25]  G. Dranoff,et al.  Gene transfer as cancer therapy. , 1995, Advances in immunology.

[26]  G. Trinchieri,et al.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. , 1994, Science.

[27]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[28]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[29]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[30]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Fujisawa,et al.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. , 1984, Journal of the National Cancer Institute.